-
British Dental Journal Sep 2021
Topics: Betamethasone; Betamethasone Valerate
PubMed: 34561568
DOI: 10.1038/s41415-021-3487-9 -
Expert Review of Clinical Immunology Feb 2017Betamethasone dipropionate has been used for the topical treatment of psoriasis in multiple formulations. DFD-01 (Sernivo™, Promius Pharma LLC) is a new midpotent... (Review)
Review
Betamethasone dipropionate has been used for the topical treatment of psoriasis in multiple formulations. DFD-01 (Sernivo™, Promius Pharma LLC) is a new midpotent lotion formulation of betamethasone dipropionate 0.05% that has recently been approved for the treatment of mild to moderate psoriasis for up to 4 weeks. Areas covered: This review will critically appraise available clinical information on DFD-01. Phase 3 efficacy and safety results will be reviewed on head-to-head comparison of DFD-01 with a superpotent augmented betamethasone dipropionate 0.05% lotion. It is suggested that the formulation of DFD-01 has enabled this midpotent topical steroid to demonstrate equivalent efficacy to a superpotent steroid. Expert commentary: DFD-01's unique advantage is that this product has the efficacy of a higher potency steroid but with the safety profile of a mid-potency steroid based on VCA assays. This formulation also has aesthetic appeal, which may benefit compliance.
Topics: Administration, Topical; Animals; Anti-Inflammatory Agents; Betamethasone; Clinical Trials, Phase III as Topic; Humans; Patient Compliance; Psoriasis; Skin Cream; Treatment Outcome
PubMed: 27967262
DOI: 10.1080/1744666X.2017.1270756 -
Cutis Feb 2020Patients consider pruritus and scaling to be the most bothersome symptoms of psoriasis. Psoriatic plaques on the knees and elbows are widely considered difficult to... (Meta-Analysis)
Meta-Analysis
Patients consider pruritus and scaling to be the most bothersome symptoms of psoriasis. Psoriatic plaques on the knees and elbows are widely considered difficult to treat because of the thicker stratum corneum, which reduces skin hydration and topical absorption. Betamethasone dipropionate (BD) spray 0.05% is a topical steroid with demonstrated efficacy in treating plaque psoriasis. Post hoc analyses of 2 phase 3 trials were done to assess the efficacy of BD spray in relieving the symptom of itching and improving the signs of erythema, scaling, and plaque elevation on plaques located on the knees and elbows vs its vehicle and an augmented BD (AugBD) lotion 0.05%. Betamethasone dipropionate spray reduced the incidence of pruritus, with approximately half of patients who reported itching at baseline showing complete itch relief by day 4. Betamethasone dipropionate spray also reduced the signs of psoriasis on knee and elbow plaques in more patients than AugBD lotion at day 4, though the differences were not statistically significant. Efficacy was similar between the 2 formulations on days 8 and 15. Betamethasone dipropionate spray rapidly relieved2 of the most bothersome symptoms of psoriasis and improved psoriatic signs in hard-to-treat knee and elbow plaques.
Topics: Administration, Cutaneous; Anti-Inflammatory Agents; Betamethasone; Humans; Psoriasis; Randomized Controlled Trials as Topic; Treatment Outcome
PubMed: 32186532
DOI: No ID Found -
JAMA Network Open May 2024
Topics: Humans; Betamethasone; Clotrimazole; Skin Diseases; Male; Female; Antifungal Agents; Practice Patterns, Physicians'; Drug Combinations; Middle Aged; Adult
PubMed: 38753333
DOI: 10.1001/jamanetworkopen.2024.11721 -
Pediatric Dermatology 2002The use of antifungal/corticosteroid combinations as topical therapy for dermatophytoses has been criticized as being less effective, more expensive, and the cause of... (Review)
Review
The use of antifungal/corticosteroid combinations as topical therapy for dermatophytoses has been criticized as being less effective, more expensive, and the cause of more adverse cutaneous reactions than antifungal monotherapy. The combination of clotrimazole and betamethasone diproprionate (Lotrisone) is a mix of an azole antifungal and a high-potency corticosteroid, and is one of the most widely prescribed of these combinations. Our objective was to describe the beneficial and deleterious effects of Lotrisone in the treatment of common cutaneous fungal infections and its relative cost-effectiveness. We did a literature review documenting clinical trial data and adverse reactions to Lotrisone and collected a cost analysis of topical antifungal prescribing data over a 2-month period from a large midwestern staff-model health maintenance organization (HMO). Lotrisone is approved by the U.S. Food and Drug Administration (FDA) for the treatment of tinea pedis, tinea cruris, and tinea corporis in adults and children more than 12 years of age. Treatment is limited to 2 weeks in the groin area and 4 weeks on the feet. The most concerning adverse effects of Lotrisone were reported in children and included treatment failure, striae distensae, hirsuitism, and growth retardation. This combination was also reported to have decreased efficacy in clearing candidal and Trichophyton infections as compared to single-agent antifungals. Lotrisone was considerably more expensive than clotrimazole alone and was found to account for more than 50% of topical antifungal expenditures as prescribed by primary care physicians, but only 7% of topical antifungals prescribed by dermatologists. We found that Lotrisone was shown to have the potential to induce many steroid-related side effects and to be less cost effective than antifungal monotherapy. This combination should be used judiciously in the treatment of cutaneous fungal infections and may not be appropriate for use in children.
Topics: Administration, Topical; Anti-Inflammatory Agents; Antifungal Agents; Betamethasone; Clotrimazole; Cost-Benefit Analysis; Dermatomycoses; Drug Combinations; Drug Costs; Glucocorticoids; Humans
PubMed: 11860579
DOI: 10.1046/j.1525-1470.2002.00027.x -
Revue Medicale de Liege Nov 2005The topical treatment of psoriasis benefits from the alternate use of dermocorticosteroids and vitamin D3 analogues. A new galenic formulation allows to combine them in... (Review)
Review
The topical treatment of psoriasis benefits from the alternate use of dermocorticosteroids and vitamin D3 analogues. A new galenic formulation allows to combine them in a single application. Dovobet (LEO Pharma) ointment is the association of calcipotriol 50 microg/g with betamethasone dipoprionate 0.5 mg/g. This formulation boosts the therapeutic activity of calcipotriol. It also decreases the irritative inflammatory reaction due to calcipotriol without increasing the atrophogenic risk of the dermocorticoid.
Topics: Administration, Topical; Betamethasone; Calcitriol; Drug Therapy, Combination; Humans; Inflammation; Psoriasis
PubMed: 16402537
DOI: No ID Found -
American Journal of Obstetrics and... Dec 2009We hypothesized that maternal treatments with betamethasone acetate induce fetal lung maturation comparably to the betamethasone phosphate+betamethasone acetate used...
OBJECTIVE
We hypothesized that maternal treatments with betamethasone acetate induce fetal lung maturation comparably to the betamethasone phosphate+betamethasone acetate used clinically.
STUDY DESIGN
Ewes with singleton pregnancies were treated with single doses of 0.25-mg/kg or 0.5-mg/kg betamethasone acetate, 4 doses of 0.25-mg/kg betamethasone phosphate, a single dose of 0.5-mg/kg betamethasone acetate+0.25-mg/kg betamethasone phosphate, 2 doses of 0.25-mg/kg betamethasone acetate+0.25-mg betamethasone phosphate or vehicle beginning 48 hours before preterm delivery. Fetal lung maturation was evaluated.
RESULTS
All treatments induced lung maturation relative to vehicle controls. The relatively insoluble betamethasone acetate resulted in low maternal blood betamethasone and no detectable fetal blood betamethasone in 2 of 3 fetuses, but it induced fetal lung maturation comparable to the 2-dose betamethasone acetate+betamethasone phosphate or 4 doses of betamethasone phosphate.
CONCLUSION
A single maternal dose of betamethasone acetate effectively induces fetal lung maturation in sheep with minimal fetal exposure.
Topics: Animals; Betamethasone; Female; Fetal Organ Maturity; Fetus; Glucocorticoids; Lung; Pregnancy; Sheep
PubMed: 19800603
DOI: 10.1016/j.ajog.2009.07.014 -
Archives of Dermatology Jan 1985
Topics: Betamethasone; Clobetasol; Eyelid Diseases; Humans; Vitiligo
PubMed: 3966813
DOI: No ID Found -
Acta Anaesthesiologica Scandinavica May 2019A preliminary study has shown effective cancer pain relief by intrathecal betamethasone (ITB). However, further evidence is needed to support this new approach.
BACKGROUND
A preliminary study has shown effective cancer pain relief by intrathecal betamethasone (ITB). However, further evidence is needed to support this new approach.
METHODS
Cancer patients with opioid-resistant pain received lumbar intrathecal administration of betamethasone 2 or 3 mg once a week for 28 days. Immediate and short-term analgesia (using a percentage pain reduction scale and a numerical rating scale, NRS) and long-term analgesia (using NRS) were assessed. Patients were classified into two groups according to the most painful site of metastasis: vertebral column and/or surrounding nerve plexus metastases (group A) and other metastases distal from the vertebral column (group B).
RESULTS
A total of 104 patients received ITB. Pain relief was observed not only in the lower half but also in the upper half of the body. The proportion of group A patients who experienced immediate analgesia was 81% (47/58), which was significantly greater than that of group B (P < 0.001). A decrease in NRS scores 1 day after ITB administration was observed in significantly more patients in group A than in group B (P < 0.001). Long-term analgesia was also recorded in a greater proportion of patients in group A than in group B in the 7-day (59%, 38/64 vs 6%, 2/33) and 28-day periods (71%, 40/56 vs 31%, 8/26) (P < 0.001). No adverse effects related to neurotoxicity were recorded.
CONCLUSION
Intrathecal injection of betamethasone produced analgesia for opioid-resistant cancer pain, and may be a potent therapeutic option for intolerable pain from vertebral column and/or surrounding nerve plexus metastases.
Topics: Aged; Analgesics; Betamethasone; Bone Neoplasms; Cancer Pain; Female; Humans; Injections, Spinal; Male; Middle Aged
PubMed: 30536525
DOI: 10.1111/aas.13305 -
Hand (New York, N.Y.) Oct 2023It is common practice for hand surgeons to premix corticosteroids with a local anesthetic and store the mixture in pre-loaded syringes for rapid use during clinic....
BACKGROUND
It is common practice for hand surgeons to premix corticosteroids with a local anesthetic and store the mixture in pre-loaded syringes for rapid use during clinic. However, any possible loss of efficacy with this practice has never been studied. The purpose of this study, therefore, is to determine whether premixing betamethasone sodium phosphate/betamethasone acetate (BSP) and lidocaine (L) at different time intervals from injection has diminishing anti-inflammatory effects on chondrocytes .
METHODS
Human articular chondrocytes were partitioned into six groups: two controls and four experimental conditions. The negative control had growth media only. The positive control had growth media and inflammatory cytokines (interleukin-1β and oncostatin M). Experimental conditions were additionally treated with BSP alone or BSP mixed with lidocaine (BSP + L) at the time of treatment (0 hours), or at 4 or 24 hours prior. Relative expressions of inflammatory genes were measured.
RESULTS
Relative to the positive control, chondrocytes in all experimental conditions decreased expression of TNF-α, MMP-3, and ADAMTS-4. Chondrocytes exposed to BSP only or BSP + L at 4 hours or 24 hours prior to treatment decreased expression of IL-8. Chondrocytes exposed to BSP only or BSP + L at 0 hours or 4 hours prior to treatment decreased expression of MMP-1. There were no significant differences in expression of IL-6 or MMP-13.
CONCLUSIONS
Treatment with BSP + L prepared in pre-loaded syringes at varying time intervals up to 24 hours prior to injection does not significantly impact the ability of the mixture to reduce expression of certain key inflammatory mediators .
Topics: Humans; Chondrocytes; Betamethasone; Lidocaine; Inflammation; Anesthetics, Local
PubMed: 35193419
DOI: 10.1177/15589447221077346